Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer

被引:1
|
作者
Van der Vorst, Aline [1 ]
Kindts, Isabelle [2 ]
Laenen, Annouschka [3 ]
Neven, Patrick [4 ]
Janssen, Hilde [1 ]
Weltens, Caroline [1 ]
机构
[1] UZ Leuven, Dept Radiat Oncol, Herestr 49, B-3000 Leuven, Belgium
[2] AZ Groeninge, Dept Radiat Oncol, President Kennedylaan 4, B-8500 Kortrijk, Belgium
[3] UZ Leuven, Dept Biostat & Stat Bioinformat, Herestr 49, B-3000 Leuven, Belgium
[4] UZ Leuven, Dept Gynaecol, Herestr 49, B-3000 Leuven, Belgium
来源
BREAST | 2022年 / 64卷
关键词
Breast cancer; Radiotherapy; Mastectomy; Locoregional recurrence; Prognostic scoring system; RADIOTHERAPY; AXILLARY; MASTECTOMY; WOMEN; RISK; TUMOR; PREDICTIONS; DIAGNOSIS; MORTALITY; SURVIVAL;
D O I
10.1016/j.breast.2022.04.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To date, it remains unclear which patients with breast cancer (BC) benefit from post-mastectomy radiotherapy (PMRT). Cheng et al. developed and validated a scoring system based on 4 prognostic factors for locoregional recurrence (LRR) to identify patients in need for PMRT. These factors include age, estrogen receptor status, lymphovascular status and number of affected axillary lymph nodes. Purpose: To validate the scoring system for LRR in BC developed by Cheng et al. by using an independent BC database. Methods and materials: We retrospectively identified 1989 BC cases, treated with mastectomy (ME) with or without PMRT at the University Hospitals Leuven between 2000 and 2007. The primary endpoint was 5-year locoregional control rate with and without PMRT, according to the LRR score. Results: Median follow-up time was 11.4 years. After excluding patients with missing variables 1103 patients were classified using the LRR scoring system: 688 (62.38%) patients were at low risk of recurrence (LRR score 0-1), 335 (30.37%) patients were at intermediate risk of recurrence (LRR score 2-3) and 80 (7.25%) patients were at high risk of recurrence (LRR score >= 4). 5-year locoregional control rates with and without PMRT were 99.20% versus 99.21% (p = 0.43) in the low-risk group; 98.24% versus 85.74% (p < 0.0001) in the intermediate-risk group and 96.87% versus 85.71% (p = 0.10) in the high-risk group respectively. Conclusion: Our validation of the LRR scoring system suggests it can be used to point out patients that would benefit from PMRT. We recommend further validation of this scoring system by other independent institutions-before application in clinical practice.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 50 条
  • [41] A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
    Anuhya Kommalapati
    Sri Harsha Tella
    Gaurav Goyal
    Apar Kishor Ganti
    Jairam Krishnamurthy
    Pavan Kumar Tandra
    Breast Cancer Research and Treatment, 2018, 170 : 677 - 685
  • [42] Validation of gene expression profiling in prediction of locoregional recurrence for breast cancer patients after surgery
    Cheng, H-C S.
    Horng, C-F
    Huang, T-T
    Tsou, M-H
    Shih, L-S
    Yu, B-L
    Tsai, Y-C
    Chen, C-M
    CANCER RESEARCH, 2016, 76
  • [43] A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
    Kommalapati, Anuhya
    Tella, Harsha
    Goyal, Gaurav
    Ganti, Apar Kishor
    Krishnamurthy, Jairam
    Tandra, Pavan Kumar
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (03) : 677 - 685
  • [44] Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes
    Li, Q.
    Wu, S.
    Zhou, J.
    Sun, J.
    Li, F.
    Lin, Q.
    Guan, X.
    Lin, H.
    He, Z.
    CURRENT ONCOLOGY, 2014, 21 (05) : E685 - E690
  • [45] The impact of surgical techniques on locoregional recurrence in breast cancer
    F. J. Fleming
    B. M. Corkery
    L. M. Kelly
    B. Dijkstra
    E. W. Mc Dermott
    A. D. K. Hill
    N. O’Higgins
    Irish Journal of Medical Science, 2002, 171 (Suppl 1)
  • [46] Current Strategies for the Management of Locoregional Breast Cancer Recurrence
    Wapnir, Irene L.
    Khan, Atif
    ONCOLOGY-NEW YORK, 2019, 33 (01): : 19 - 25
  • [47] Locoregional recurrence after initial therapy for breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 160 - 160
  • [48] Locoregional Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
    Carr, M. J.
    Sun, J.
    Kiluk, J. V.
    Sun, W.
    Zhou, J.
    Kim, Y.
    Laronga, C.
    Lee, M. C.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S147 - S148
  • [49] Risk Factors of the Invasive Breast Cancer Locoregional Recurrence
    Liubota, R. V.
    Zotov, A. S.
    Vereshchako, R. I.
    Liubota, I. I.
    Zaychuk, V. V.
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [50] Role of Hyperthermia in Breast Cancer Locoregional Recurrence: A Review
    Maluta, Sergio
    Kolff, Merel Willemijn
    BREAST CARE, 2015, 10 (06) : 408 - 412